Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Plasma Anti-Mullerian Hormone in Breast Cancer

Cancer Epidemiol Biomarkers Prev; ePub 2016 Mar 9; Eliassen, et al

Higher circulating anti-Müllerian hormone (AMH) levels are associated with increased breast cancer risk among premenopausal women, according to a study of blood samples from 62,437 women, including 539 who were later diagnosed with breast cancer and 539 matched controls. Researchers found:

• Higher plasma levels of AMH were associated with increased breast cancer risk (top vs bottom quintile OR=2.20).

• This association did not vary by invasive vs in situ disease or by estrogen receptor status.

• Associations were not significantly different by age at blood sampling or at diagnosis.

• Additional adjustment for plasma estradiol or testosterone yielded similar results.

Citation: Eliassen AH, Zeleniuch-Jacquotte A, Rosner B, Hankinson SE. Plasma anti-Müllerian hormone concentrations and risk of breast cancer among premenopausal women in the Nurses' Health Studies. [Published online ahead of print March 9, 2016]. Cancer Epidemiol Biomarkers Prev. doi:10.1158/1055-9965.EPI-15-1240.